Following the approval of direct oral anticoagulants (DOACs) a number of real-world studies were initiated to look at their impact on atrial fibrillation (AF) patients seen in daily practice. Unlike randomized controlled trials, real-world studies do not have strict exclusion criteria and look include many AF patients with various comorbidities. However, there are fundamental differences in the real-world studies that have been conducted.
We met with experts (Professor Jan Tijssen from the University of Amsterdam and Professor Menno Huisman from Leiden University Medical Center) to discuss what is the basis of a well-designed real-world study.
This discussion was made possible by Boehringer Ingelheim.
Get our free eBook, Cardiology Best Practices, for a comprehensive look at the top position papers, consensus reports and more cardiology news important for daily practice.